<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03120182</url>
  </required_header>
  <id_info>
    <org_study_id>SECA</org_study_id>
    <nct_id>NCT03120182</nct_id>
  </id_info>
  <brief_title>Chronic Subdural Hematoma and Aspirin</brief_title>
  <acronym>SECA</acronym>
  <official_title>Impact of Perioperative Maintenance or Interruption of Low-dose Aspirin on Recurrence Rate and Thrombotic Events After Burr-hole Drainage of Chronic Subdural Hematoma: a Randomized, Placebo Controlled, Double Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized, blinded, placebo controlled clinical study is to compare the
      peri- and postoperative bleeding and cardiovascular complication rates of patients undergoing
      burr-hole trepanation for chronic subdural hematoma with and without discontinuation of
      low-dose aspirin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic subdural hematoma (cSDH) is one of the most common neurosurgical conditions. Its
      significantly higher prevalence among patients older than 65 (69%) versus younger (31%)
      explains why 41% of the patients are taking blood thinners. Antiplatelet therapy in patients
      with chronic subdural hematoma (cSDH) presents significant neurosurgical challenges. Studies
      investigating the effect of acetylsalicylic acid (ASA) in cranial neurosurgery are sparse and
      mostly based on case reports. Given the lack of guidelines regarding perioperative management
      with antiplatelet therapy, it is difficult to balance the patient's increased cardiovascular
      risk and prevalence of cSDH. The aim of our randomized, blinded, placebo controlled clinical
      study is to compare the peri- and postoperative bleeding and cardiovascular complication
      rates of patients undergoing burr-hole trepanation for cSDH with and without discontinuation
      of low-dose ASA. We will include patients receiving low-dose ASA as secondary prophylaxis for
      various reasons (e.g. coronary artery disease (CAD), cerebrovascular disease, etc.) and will
      randomize them either to a Placebo- or Aspirin-arm. The patients will receive placebo or ASA
      for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization. Our
      study primarily seeks to evaluate the risk of recurrence after burr-hole trepanation for cSDH
      under low-dose ASA treatment compared to placebo treatment. Secondary objectives are to
      assess the rate of thrombotic events, perioperative blood loss, postoperative anemia, intra-
      and postoperative blood transfusion rate, and clinical outcome (mRS, GOS, Markwalder score).
      The study will be performed in cooperation with the Department of Cardiology of the
      University Hospital of Basel.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo controlled, double blinded study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blinded study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Revision surgery due to a recurrent subdural hematoma</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrence of chronic subdural hematoma requiring revision surgery (burr-hole drainage)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 months</time_frame>
    <description>(STEMI/non-STEMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>6 months</time_frame>
    <description>cerebral stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral arterial occlusion</measure>
    <time_frame>6 months</time_frame>
    <description>occlusion of a peripheral artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other bleeding events apart from recurrent chronic subdural hematoma managed operatively or conservatively</measure>
    <time_frame>6 months</time_frame>
    <description>acute subdural hematoma (aSDH), acute epidural hematoma (EDH), intraparenchymal bleeding)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>on the operation day (up to 1 day)</time_frame>
    <description>blood loss recorded during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of blood/ fluid collected in the drain</measure>
    <time_frame>up to 2 days, at removal of the drainage</time_frame>
    <description>Amount of blood/ fluid collected in the drain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative anemia</measure>
    <time_frame>up to 7 days</time_frame>
    <description>hemoglobin&lt;80mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>during surgery</time_frame>
    <description>Operation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization time</measure>
    <time_frame>an average of 7 days</time_frame>
    <description>Hospitalization time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood transfusion rate</measure>
    <time_frame>during surgery (e.g. up to 1 day)</time_frame>
    <description>blood transfusion rate intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative blood transfusion rate</measure>
    <time_frame>during hospitalization, an average of 7 days</time_frame>
    <description>blood transfusion rate postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GCS Score</measure>
    <time_frame>6 months</time_frame>
    <description>Glasgow Coma Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS</measure>
    <time_frame>6 months</time_frame>
    <description>modified Rankin scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GOS</measure>
    <time_frame>6 months</time_frame>
    <description>Glasgow Outcome Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>6 months</time_frame>
    <description>Markwalder Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Aspirin Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will receive acetylsalicylic acid (100mg once a day, orally) for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients will receive placebo oral tablets for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization</description>
    <arm_group_label>Aspirin Arm</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Patients will receive placebo medication 100mg daily for 12 days after randomization</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing burr hole trepanation for cSDH who are under low-dose aspirin
             treatment ( Aspirin cardio 100mg once a day) for secondary prophylaxis

        Exclusion Criteria:

          -  Patients under the age of 18years

          -  A recent (30 days before randomization) major cardiac event (i.e. unstable angina,
             myocardial infarction, or coronary revascularization)

          -  A recent (30 days before randomization) active bleeding event.

          -  Patient with known bleeding disorder (e.g. hemophilia)

          -  No informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Mariani, Prof, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Neurosurgery, University Hospital Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Kamenova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, University Hospital Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jehuda Soleman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Kamenova, MD</last_name>
    <phone>00413287814</phone>
    <email>maria.kamenova@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jehuda Soleman, MD</last_name>
    <email>jehuda.soleman@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurosurgery</name>
      <address>
        <city>Basel</city>
        <zip>4053</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Kamenova, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Maria Kamenova</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>bleeding risk</keyword>
  <keyword>intracranial bleeding</keyword>
  <keyword>burr-hole drainage</keyword>
  <keyword>chronic subdural hematoma</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

